Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142


Real-life effectiveness of indacaterol-glycopyrronium after switching from tiotropium or salmeterol/fluticasone therapy in patients with symptomatic COPD: the POWER study.

Kaplan A, Chapman KR, Anees SM, Mayers I, Rochdi D, Djandji M, Préfontaine D, McIvor A.

Int J Chron Obstruct Pulmon Dis. 2019 Jan 18;14:249-260. doi: 10.2147/COPD.S185485. eCollection 2019.


Efficacy and safety of the direct switch to indacaterol/glycopyrronium from salmeterol/fluticasone in non-frequently exacerbating COPD patients: The FLASH randomized controlled trial.

Frith PA, Ashmawi S, Krishnamurthy S, Gurgun A, Hristoskova S, Pilipovic V, Hamann AM, Backer A, Olsson P, Kostikas K, Diaz DV; FLASH Investigators.

Respirology. 2018 Dec;23(12):1152-1159. doi: 10.1111/resp.13374. Epub 2018 Aug 3.


Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial.

Vogelmeier CF, Gaga M, Aalamian-Mattheis M, Greulich T, Marin JM, Castellani W, Ninane V, Lane S, Nunez X, Patalano F, Clemens A, Kostikas K; CRYSTAL study investigators.

Respir Res. 2017 Jul 18;18(1):140. doi: 10.1186/s12931-017-0622-x.


The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD.

Anzueto AR, Vogelmeier CF, Kostikas K, Mezzi K, Fucile S, Bader G, Shen S, Banerji D, Fogel R.

Int J Chron Obstruct Pulmon Dis. 2017 May 4;12:1325-1337. doi: 10.2147/COPD.S133307. eCollection 2017.


Efficacy and safety of indacaterol/glycopyrronium fixed-dose combination in mild-to-moderate COPD patients symptomatic on tiotropium in Korea: study protocol for a randomized controlled trial.

Rhee CK, Park HY, Park JW, Lee JH, Kim TH, Lee SW, Jung JY, Kim S, Hwang YI, Jung KS.

Trials. 2017 Feb 22;18(1):80. doi: 10.1186/s13063-017-1800-3.


Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study.

Greulich T, Kostikas K, Gaga M, Aalamian-Mattheis M, Lossi NS, Patalano F, Nunez X, Pagano VA, Fogel R, Vogelmeier CF, Clemens A.

Int J Chron Obstruct Pulmon Dis. 2018 Apr 16;13:1229-1237. doi: 10.2147/COPD.S159732. eCollection 2018.


Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis.

Vogelmeier C, Zhong N, Humphries MJ, Mezzi K, Fogel R, Bader G, Patalano F, Banerji D.

Int J Chron Obstruct Pulmon Dis. 2016 Dec 14;11:3189-3197. doi: 10.2147/COPD.S116786. eCollection 2016.


Indacaterol/glycopyrronium versus salmeterol/fluticasone in Asian patients with COPD at a high risk of exacerbations: results from the FLAME study.

Wedzicha JA, Zhong N, Ichinose M, Humphries M, Fogel R, Thach C, Patalano F, Banerji D.

Int J Chron Obstruct Pulmon Dis. 2017 Jan 19;12:339-349. doi: 10.2147/COPD.S125058. eCollection 2017.


Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD.

Chan MC, Tan EC, Yang MC.

Int J Chron Obstruct Pulmon Dis. 2018 Apr 4;13:1079-1088. doi: 10.2147/COPD.S159103. eCollection 2018.


Efficacy and safety of coadministration of once-daily indacaterol and glycopyrronium versus indacaterol alone in COPD patients: the GLOW6 study.

Vincken W, Aumann J, Chen H, Henley M, McBryan D, Goyal P.

Int J Chron Obstruct Pulmon Dis. 2014 Feb 24;9:215-28. doi: 10.2147/COPD.S51592. eCollection 2014.


LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.

Zhong N, Wang C, Zhou X, Zhang N, Humphries M, Wang L, Thach C, Patalano F, Banerji D; LANTERN Investigators.

Int J Chron Obstruct Pulmon Dis. 2015 Jun 5;10:1015-26. doi: 10.2147/COPD.S84436. eCollection 2015.


Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE study.

Hashimoto S, Ikeuchi H, Murata S, Kitawaki T, Ikeda K, Banerji D.

Int J Chron Obstruct Pulmon Dis. 2016 Oct 11;11:2543-2551. eCollection 2016. Erratum in: Int J Chron Obstruct Pulmon Dis. 2017 Jan 10;12 :231.


Exacerbation heterogeneity in COPD: subgroup analyses from the FLAME study.

Vogelmeier CF, Chapman KR, Miravitlles M, Roche N, Vestbo J, Thach C, Banerji D, Fogel R, Patalano F, Olsson P, Kostikas K, Wedzicha JA.

Int J Chron Obstruct Pulmon Dis. 2018 Apr 10;13:1125-1134. doi: 10.2147/COPD.S160011. eCollection 2018.


Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US.

Rajagopalan K, Bloudek L, Marvel J, Dembek C, Kavati A.

Int J Chron Obstruct Pulmon Dis. 2018 Nov 28;13:3867-3877. doi: 10.2147/COPD.S177097. eCollection 2018.


A randomized trial to determine the impact of indacaterol/glycopyrronium on nighttime oxygenation and symptoms in patients with moderate-to-severe COPD: the DuoSleep study.

Lehmann S, Ringbæk T, Løkke A, Grote L, Hedner J, Lindberg E.

Int J Chron Obstruct Pulmon Dis. 2019 Jan 9;14:199-210. doi: 10.2147/COPD.S184127. eCollection 2019.


Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study.

Dahl R, Jadayel D, Alagappan VK, Chen H, Banerji D.

Int J Chron Obstruct Pulmon Dis. 2013;8:501-8. doi: 10.2147/COPD.S49615. Epub 2013 Oct 17. Erratum in: Int J Chron Obstruct Pulmon Dis. 2014;9:85. Dosage error in published abstract; MEDLINE/PubMed abstract corrected; Dosage error in article text.


Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study.

Beeh KM, Kirsten AM, Tanase AM, Richard A, Cao W, Hederer B, Beier J, Kornmann O, van Zyl-Smit RN.

Int J Chron Obstruct Pulmon Dis. 2018 Dec 6;13:3923-3936. doi: 10.2147/COPD.S179293. eCollection 2018.

Supplemental Content

Support Center